Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glufosfamide vs Best Supportive Care in Gemcitabine-Pretreated Metastatic Pancreatic Adenocarcinoma
2004-001363-22Phase 3Completed
- Sponsor
- Threshold Pharmaceuticals
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Glufosfamide with Best supportive care (2 arms). Primary endpoints: Overall survival and Safety. Started Aug 2004; status: completed.
02
Drugs
glufosfamide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2004-001363-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001363-22.